Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affordability board and its decision to place a ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Dividend investing is an excellent strategy for (at least) two reasons. Here are two companies that can pull it off: Amgen ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...